Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junliang Li

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
JAMA Oncology|January 2, 2026
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical TrialXinan Sheng, Gang Huang, Meiyu Fang, et al.
Nature Food|April 28, 2023
Innovative management programme reduces environmental impacts in Chinese vegetable productionXiaozhong Wang, Zhengxia Dou, Xiaojun Shi, et al.
The Lancet. Oncology|September 8, 2022
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trialWeijie Gu, Weiqing Han, Hong Luo, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
JAMA Oncology|January 2, 2026
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical TrialXinan Sheng, Gang Huang, Meiyu Fang, et al.
Nature Food|April 28, 2023
Innovative management programme reduces environmental impacts in Chinese vegetable productionXiaozhong Wang, Zhengxia Dou, Xiaojun Shi, et al.
The Lancet. Oncology|September 8, 2022
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trialWeijie Gu, Weiqing Han, Hong Luo, et al.
Pageof 12